BNP/CALL/ELI LILLY & CO/650/0.1/17.01.25 | Market Closed - Boerse Frankfurt Warrants 01:20:35 06/07/2024 am IST | ||
| 26.9 EUR | +4.10% |
|
| Current month | +1.01% | ||
| 1 month | +33.88% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 05/24/05 | 26.99 | +4.45% |
| 04/24/04 | 25.84 | +0.86% |
| 03/24/03 | 25.62 | -3.54% |
| 02/24/02 | 26.56 | -1.30% |
| 01/24/01 | 26.91 | +0.71% |
Real-time Boerse Frankfurt Warrants
Last update July 06, 2024 at 01:20 am IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
BNP Paribas
|
| WKN | PZ1XP7 |
| ISIN | DE000PZ1XP78 |
| Date issued | 30/11/2023 |
| Strike | 650 $ |
| Maturity | 17/01/2025 (195 Days) |
| Parity | 10 : 1 |
| Emission price | 6.46 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 27.37 € |
|---|---|
| Lowest since issue | 5.23 € |
| Spread | 0.02 € |
| Spread % | 0.07% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
914.6
USD
Average target price
870.3
USD
Spread / Average Target
-4.84%
- Stock Market
- Warrants
- Warrant
